Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C58H73N13O21S2.C4H11N |
| Molecular Weight | 1425.542 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC.[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]2CCC(=O)N2)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC3=CNC4=CC=CC=C34)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC5=CC=CC=C5)C(N)=O
InChI
InChIKey=FHDKSYKZXIFRKJ-CBCFNHQSSA-N
InChI=1S/C58H73N13O21S2.C4H11N/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30;1-3-5-4-2/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91);5H,3-4H2,1-2H3/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+;/m1./s1
CERULETIDE, also known as caerulein, is a specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. It is similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. In the research setting, CERULETIDE can be used to induce pancreatitis in experimental animal models.
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.6 ug/kg 2 times / day multiple, intravenous Studied dose Dose: 0.6 ug/kg, 2 times / day Route: intravenous Route: multiple Dose: 0.6 ug/kg, 2 times / day Sources: Page: p.1483 |
unhealthy, 16 n = 16 Health Status: unhealthy Condition: Schizophrenia Age Group: 16 Population Size: 16 Sources: Page: p.1483 |
Disc. AE: Abdominal cramps... AEs leading to discontinuation/dose reduction: Abdominal cramps (grade 1-2, 31.2%) Sources: Page: p.1483 |
20 ug single, intramuscular Highest studied dose Dose: 20 ug Route: intramuscular Route: single Dose: 20 ug Sources: Page: p.517 |
healthy, 20-32 n = 16 Health Status: healthy Condition: Pain Age Group: 20-32 Sex: M Population Size: 16 Sources: Page: p.517 |
Other AEs: Sickness, Dizziness... Other AEs: Sickness (grade 1, 12.5%) Sources: Page: p.517Dizziness (grade 1, 12.5%) Headache (grade 1, 6.25%) Injection site pain (grade 1, 50%) |
100 ng/kg/h single, intravenous Studied dose Dose: 100 ng/kg/h Route: intravenous Route: single Dose: 100 ng/kg/h Co-administed with:: secretin iv(1 CU/kg/h) Sources: Page: p.226 |
unhealthy, 24-55 n = 6 Health Status: unhealthy Condition: Chronic pancreatitis Age Group: 24-55 Population Size: 6 Sources: Page: p.226 |
|
0.6 ug/kg 2 times / day multiple, intravenous Studied dose Dose: 0.6 ug/kg, 2 times / day Route: intravenous Route: multiple Dose: 0.6 ug/kg, 2 times / day Sources: Page: p.1483 |
unhealthy n = 16 Health Status: unhealthy Condition: Schizophrenia Population Size: 16 Sources: Page: p.1483 |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 31.2%) Sources: Page: p.1483 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Abdominal cramps | grade 1-2, 31.2% Disc. AE |
0.6 ug/kg 2 times / day multiple, intravenous Studied dose Dose: 0.6 ug/kg, 2 times / day Route: intravenous Route: multiple Dose: 0.6 ug/kg, 2 times / day Sources: Page: p.1483 |
unhealthy, 16 n = 16 Health Status: unhealthy Condition: Schizophrenia Age Group: 16 Population Size: 16 Sources: Page: p.1483 |
| Dizziness | grade 1, 12.5% | 20 ug single, intramuscular Highest studied dose Dose: 20 ug Route: intramuscular Route: single Dose: 20 ug Sources: Page: p.517 |
healthy, 20-32 n = 16 Health Status: healthy Condition: Pain Age Group: 20-32 Sex: M Population Size: 16 Sources: Page: p.517 |
| Sickness | grade 1, 12.5% | 20 ug single, intramuscular Highest studied dose Dose: 20 ug Route: intramuscular Route: single Dose: 20 ug Sources: Page: p.517 |
healthy, 20-32 n = 16 Health Status: healthy Condition: Pain Age Group: 20-32 Sex: M Population Size: 16 Sources: Page: p.517 |
| Injection site pain | grade 1, 50% | 20 ug single, intramuscular Highest studied dose Dose: 20 ug Route: intramuscular Route: single Dose: 20 ug Sources: Page: p.517 |
healthy, 20-32 n = 16 Health Status: healthy Condition: Pain Age Group: 20-32 Sex: M Population Size: 16 Sources: Page: p.517 |
| Headache | grade 1, 6.25% | 20 ug single, intramuscular Highest studied dose Dose: 20 ug Route: intramuscular Route: single Dose: 20 ug Sources: Page: p.517 |
healthy, 20-32 n = 16 Health Status: healthy Condition: Pain Age Group: 20-32 Sex: M Population Size: 16 Sources: Page: p.517 |
| Vomiting | grade 1-2, 31.2% Disc. AE |
0.6 ug/kg 2 times / day multiple, intravenous Studied dose Dose: 0.6 ug/kg, 2 times / day Route: intravenous Route: multiple Dose: 0.6 ug/kg, 2 times / day Sources: Page: p.1483 |
unhealthy n = 16 Health Status: unhealthy Condition: Schizophrenia Population Size: 16 Sources: Page: p.1483 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of mast-cell stabilization in cerulein-induced acute pancreatitis in rats. | 2001 |
|
| The influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on the development of experimental acute pancreatitis. | 2001 |
|
| 6-Hydroxydopamine infusions into the structures of mesolimbic dopaminergic system alter the memory enhancing effect of CK-8US and caerulein in rats. | 2001 |
|
| [Defecation properties after coloanal reconstruction in the pig model]. | 2001 |
|
| Stress kinase inhibition modulates acute experimental pancreatitis. | 2001 Apr |
|
| Effect of sensory nerves and CGRP on the development of caerulein-induced pancreatitis and pancreatic recovery. | 2001 Dec |
|
| Does chronic ethanol administration have influence on pancreatic regeneration in the course of caerulein induced acute pancreatitis in rats. | 2001 Dec |
|
| Persantine improves acute pancreatitis in vitro. | 2001 Nov-Dec |
|
| A method using laser Doppler flowmetry to study intestinal and pancreatic perfusion during an acute intestinal ischaemic injury in rats with pancreatitis. | 2001 Sep-Dec |
|
| The gut origin of bacterial pancreatic infection during acute experimental pancreatitis in rats. | 2002 |
|
| The time course of gap-junctional protein connexin 32 expression in the pancreas after the induction of acute pancreatitis by caerulein in rats. | 2002 |
|
| Leptin modulates the inflammatory response in acute pancreatitis. | 2002 |
|
| Leptin protects the pancreas from damage induced by caerulein overstimulation by modulating cytokine production. | 2002 |
|
| Negative ion electrospray mass spectra of caerulein peptides: an aid to structural determination. | 2002 |
|
| Intracerebroventricular administration of bacterial lipopolysaccharide prevents the development of acute experimental pancreatitis in the rat. | 2002 Apr |
|
| Neutrophils and NADPH oxidase mediate intrapancreatic trypsin activation in murine experimental acute pancreatitis. | 2002 Apr |
|
| Early changes of the expression of cathepsin B mRNA during cerulein supramaximal stimulation. | 2002 Apr |
|
| Penetration of meropenem and cefepim into pancreatic tissue during the course of experimental acute pancreatitis. | 2002 Apr |
|
| Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. | 2002 Apr |
|
| Glutathione depletion with L-buthionine-(S,R)-sulfoximine demonstrates deleterious effects in acute pancreatitis of the rat. | 2002 Aug |
|
| Pancreatic capillary blood flow in an improved model of necrotizing pancreatitis in the rat. | 2002 Aug |
|
| Endothelin A but not endothelin B receptor blockade reduces capillary permeability in severe experimental pancreatitis. | 2002 Aug |
|
| Mechanisms of Chinese herb emodin and somatostatin analogs on pancreatic regeneration in acute pancreatitis in rats. | 2002 Aug |
|
| Different modes of NF-kappaB/Rel activation in pancreatic lobules. | 2002 Aug |
|
| Lung changes and cytokine levels in a model of experimental acute pancreatitis. | 2002 Feb |
|
| Acute pancreatitis decreases pancreas phospholipid levels and increases susceptibility to lipid peroxidation in rat pancreas. | 2002 Feb |
|
| Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block? | 2002 Feb |
|
| Trypsin activity is not involved in premature, intrapancreatic trypsinogen activation. | 2002 Feb |
|
| Natural history of long-term lung injury in mouse experimental pancreatitis. | 2002 Jul |
|
| The influence of cholecystokinin on gastric myoelectrical activity in duodenal ulcer following Helicobacter pylori eradication--an electrogastrographic study. | 2002 Jun |
|
| Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. | 2002 Jun 15 |
|
| Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. | 2002 Jun 7 |
|
| Amelioration of cerulein-induced acute pancreatitis by 2,2'-dipyridyl in rats. | 2002 Mar |
|
| Sensory nerves in central and peripheral control of pancreatic integrity by leptin and melatonin. | 2002 Mar |
|
| Human interleukin 10 gene therapy decreases the severity and mortality of lethal pancreatitis in rats. | 2002 Mar |
|
| Alcohols enhance caerulein-induced zymogen activation in pancreatic acinar cells. | 2002 Mar |
|
| The effects of prostaglandin E1 on the microperfusion of the pancreas during acute necrotizing pancreatitis in rats. | 2002 Mar-Apr |
|
| [The role of thiol oxidants in inhibition of pancreatic exocrine secretory function and glutathione]. | 2002 May |
|
| Selective tachykinin NK3-receptor agonists stimulate in vitro exocrine pancreatic secretion in the guinea pig. | 2002 May |
|
| Inducible nitric oxide synthase-deficient mice exhibit resistance to the acute pancreatitis induced by cerulein. | 2002 May |
|
| Pancreatic stellate cell activation and MMP production in experimental pancreatic fibrosis. | 2002 May 15 |
|
| The effects of somatostatin on the microperfusion of the pancreas during acute necrotizing pancreatitis in rats. | 2002 May-Jun |
|
| Effect of intravenous infusion of amino acids on pancreatic secretion. | 2002 May-Jun |
|
| Selective inhibition of NF-kappaB attenuates the severity of cerulein-induced acute pancreatitis. | 2002 Oct |
|
| Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. | 2002 Oct |
|
| Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059. | 2002 Oct |
|
| Primary sensory neurons: a common final pathway for inflammation in experimental pancreatitis in rats. | 2002 Oct |
|
| Effect of nitric oxide on gallbladder motility in patients with acalculous biliary pain: a cholescintigraphic study. | 2002 Sep |
|
| Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. | 2002 Sep |
|
| In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. | 2002 Sep |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID001027524
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
59223
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
275-298-0
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
C032637
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
C65310
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
100000076342
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
20024
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
71247-25-1
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
4E1MIA8QQL
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
m3274
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
DBSALT001364
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
57363-15-2
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
ALTERNATIVE | |||
|
CHEMBL1201355
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
SUB13298MIG
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
16158172
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
PRIMARY | |||
|
62152-49-2
Created by
admin on Fri Dec 15 15:29:41 UTC 2023 , Edited by admin on Fri Dec 15 15:29:41 UTC 2023
|
ALTERNATIVE |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
